Form 4: ImmuCell Corp Director Tomsche Acquires 10,000 Stock Options
SEC Form 4 Filing
Director David Scott Tomsche acquired 10,000 non-qualified stock options in ImmuCell Corp on September 20, 2024, at an exercise price of $3.60.
Summary
- On September 20, 2024, David Scott Tomsche, a director of ImmuCell Corp, acquired 10,000 non-qualified stock options.
- The exercise price for these options is $3.60.
- The options are exercisable from September 20, 2027, and expire on September 20, 2029.
- Following the transaction, Tomsche beneficially owns 10,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a stock option grant. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 09/20/2024 | Date of transaction: acquisition of 10,000 non-qualified stock options. |
| 09/20/2027 | Date the stock options become exercisable. |
| 09/20/2029 | Expiration date of the stock options. |
| 09/24/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.